Psoriasis

Psoriasis is a chronic inflammatory and proliferative skin disease that affects 2-3% of the population in western countries and an estimated 80 million people worldwide. The disease causes disfiguration in 10- 30% of cases and arthiritis in 10-15% of patients. Although attempts are made to model aspects of psoriasis in animals, none of the models reproduce the complex psoriatic phenotypes that are observed in humans. The availability of an in vitro psoriasis model to screen candidate drugs and to gain a better understanding of the biological mechanisms involved in psoriatic disease would be valuable.

Creative Bioarray provides in vitro Psoriasis skin Model (psoriatic tissue equivalent, PTE) by co-culturing of keratinocytes, fibroblasts, dendritic cells, and T-cells, and offers our customer in vitro pharmacology assays and compound testing service such as histology, ultrastructure, cytokine release, and protein expression of the Psoriasis skin Model, dedicating to the evaluation of pharmacological efficacy of your products.

Psoriasis

Your needs

To evaluation of pharmacological efficacy (screening, profiling, proof-of-concept) of your products (APIs, biosimilars, formulations, medical devices)
Need a customized in vitro efficacy tests related to skin efficacy

Our Capability

Skin models available

Normal Human Epidermal Keratinocytes
In vitro 3D Psoriasis Skin Model
Psoriasis Skin Explants (ex vivo)

Screening assays available

Evaluating pharmacological efficacy
Compound screening and profiling related to Psoriasis

Endpoint

Cell viability and skin thickness
Hyper-proliferation markers: Ki67
Pro-inflammatory markers: IL-6, IL-8, IL17, IL-23 and TNFα and other markers involved in the inflammatory response.
PGE2 expression
Functional proteins: stratifin, Filaggrin, Elafin, and psoriasin
Specific marker analysis by immunoassays or RT-qPCR

Techniques

qPCR, qPCRarray, RT-PCR
Epidermal separation
Immunofluorescence
RNA extraction
ELISA
Protein extraction

Study Examples

Fig.1 Representative photomicrographs of immunohistochemical staining showing the expression of differentiation markers in control vs. psoriasis skin model under different treatment conditions.